Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 16/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.41 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | HCK | P08631 | 1/20 | 0.41 |
| ▸ | FGR | P09769 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | CSK | P41240 | 1/20 | 0.41 |
| ▸ | BLK | P51451 | 1/20 | 0.41 |
| ▸ | BMX | P51813 | 1/20 | 0.41 |
| ▸ | SRMS | Q9H3Y6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323163 | 0.93 | CSF1R (0.43) | LCKTEKCSF1RABL1BCR | |
| SCHEMBL15907319 | 0.91 | ABL1 (0.42) | LCKTEKCSF1RABL1BCR | |
| SCHEMBL15907298 | 0.85 | DHODH (0.38) | LCKTEKCSF1RABL1BCR | |
| SCHEMBL18323139 | 0.85 | KCNQ3 (0.43) | LCKTEKCSF1RABL1BCR | |
| SCHEMBL15907267 | 0.82 | CSF1R (0.53) | LCKCSF1RABL1BCRKIT | |
| SCHEMBL15907299 | 0.81 | CSF1R (0.49) | LCKCSF1RABL1KITDDR1 | |
| SCHEMBL15907317 | 0.80 | CSF1R (0.33) | LCKTEKCSF1RABL1 | |
| SCHEMBL18323186 | 0.78 | DHODH (0.38) | ABL1BCR | |
| SCHEMBL15907171 | 0.78 | DHODH (0.48) | LCKTEKABL1BCRKIT | |
| SCHEMBL18323522 | 0.75 | ABL1 (0.45) | LCKCSF1RABL1BCRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | LCK 13/4885TEK 586/4885CSF1R 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.